Recombinant human soluble thrombomodulin as an anticoagulation therapy improves recurrent miscarriage and fetal growth restriction due to placental insufficiency – The leading cause of preeclampsia

Placental insufficiency is one of the major risk factors for growth restriction and preeclampsia. The aim of this study is to investigate whether recombinant human Thrombomodulin(r-TM) improves fetal conditions and physiological outcomes.

Source: Placenta - March 26, 2018 Category: Reproduction Medicine Authors: Takumi Sano, Yoshito Terai, Atsushi Daimon, Misa Nunode, Yoko Nagayasu, Atsuko Okamoto, Daisuke Fujita, Masami Hayashi, Masahide Ohmichi Source Type: research